SPT Labtech opens new office to maximise on Japanese biotech growth
This is the company's second site in the APAC region, headed by Masahiro Matsushita.
The expansion follows long-standing partnerships with Japanese life science distributors.
The move was motivated, in part, by growing biotech and healthcare markets in Japan. The increasing importance of the Japanese life science market and investment in valued techniques such as NGS and cryo-EM, coupled with the desire to further improve the connection to its customers, are all key contributors to SPT Labtech’s enhanced presence in the region.
Through world-leading application knowledge and engineering capabilities, SPT Labtech has designed and built a portfolio of liquid handling and sample management solutions that help improve efficiency, increase agility, support miniaturisation and streamline life science research. The range includes solutions for use across drug discovery, structural biology, genomics, cryo-EM, sample management and biobanking.
David Newble, Managing Director of SPT Labtech, said: "Our ambition is to strengthen the company’s partnerships within the Japanese market and the establishment of a team in Japan will enable SPT Labtech to meet the needs of this community more effectively. From our existing sector presence, there is already much interest for our products and through collaboration, deep application knowledge and world-leading engineering, we look forward to working with more life scientists to help accelerate and elevate their research."
Masahiro Matsushita, Director SPT Labtech Japan, commented: "With a flourishing life sciences industry in Japan and increasing adoption of laboratory automation, this is an ideal time for SPT Labtech to fully embed themselves in the region. With the opening of the new office, we are looking ahead to a collaborative future that will benefit clients and the life sciences community in Japan."
Scenic Biotech awarded fund to progress immuno-oncology program READ MORE
Symbiosis secures £1 million of growth finance from Allied Irish Bank READ MORE
Proteomics on NGS: Why this new launch could be a game changer READ MORE
British Patient Capital invests in life-changing biotech companies READ MORE
Novavax and UK government announce deal for COVID-19 vaccine candidate READ MORE